Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,801 to 3,820 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With at Least One On-treatment Bone Fracture Incident in the Treatment Period | 4 of 911 6 of 899 | -0.2 points -1.1 to 0.5 | 1,810 | NCT02345161 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With an On-treatment Penumonia Event in the Treatment Period | 20 of 911 7 of 899 | 1.4 points 0.3 to 2.7 | 1,810 | NCT02345161 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: serious adverse events | 61 of 911 64 of 899 | -0.4 points -2.8 to 1.9 | 1,810 | NCT02345161 A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Standard Monitor (24) vs Large Monitor (32): Polyp Detection Rate (All Indications) | 367 of 910 424 of 895 | -7.0 points -11.6 to -2.5 | 1,805 | NCT01952418 Effect of Video Monitor Size on Adenoma Detection Rate |
| Standard Monitor (24) vs Large Monitor (32): Adenoma Detection Rate (All Indications) | 264 of 910 271 of 895 | -1.3 points -5.5 to 2.9 | 1,805 | NCT01952418 Effect of Video Monitor Size on Adenoma Detection Rate |
| High Tranfusion Threshold vs Low Transfusion Threshold: deaths from any cause | 146 of 903 135 of 901 | 1.2 points -2.2 to 4.5 | 1,804 | NCT01702805 Transfusion of Prematures Trial |
| LTFU (EXT2): Early Vaccination Group vs LTFU (EXT2): Catch-up Vaccination Group: LTFU (EXT2): Number of Participants Who Died | 5 of 936 2 of 867 | 0.3 points -0.4 to 1.0 | 1,803 | NCT00090285 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) |
| dPly-PhtD Group vs Control Group: Number of Subjects With Any Serious Adverse Events (SAEs) | 229 of 900 232 of 903 | -0.2 points -4.3 to 3.8 | 1,803 | NCT01545375 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children |
| dPly-PhtD Group vs Control Group: Number of Subjects With Any Acute Otitis Media (AOM) With Temporally Related Carriage | 338 of 900 368 of 903 | -3.2 points -7.7 to 1.3 | 1,803 | NCT01545375 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children |
| dPly-PhtD Group vs Control Group: Number of Subjects With Any Recurrent Healthcare Provider Diagnosed Acute Otitis Media (AOM) | 30 of 900 32 of 903 | -0.2 points -1.9 to 1.5 | 1,803 | NCT01545375 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children |
| dPly/PhtD Group vs Control Group: serious adverse events | 229 of 900 232 of 903 | -0.2 points -4.3 to 3.8 | 1,803 | NCT01545375 Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children |
| CABG vs PCI With DES: serious adverse events | 391 of 897 357 of 903 | 4.1 points -0.5 to 8.6 | 1,800 | NCT00114972 SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries |
| Greenlight Plus vs Greenlight: deaths from any cause | 0 of 898 2 of 902 | -0.2 points -0.8 to 0.2 | 1,800 | NCT04042467 Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention |
| mRNA-1273.712 vs Placebo: Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2) | 1 of 890 0 of 910 | 0.1 points -0.3 to 0.6 | 1,800 | NCT06634797 A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age |
| Absorb BVS vs XIENCE: Number of Cardiac Death/All MI | 185 of 1,187 81 of 612 | 2.4 points -1.2 to 5.6 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 85 of 1,187 44 of 612 | -0.0 points -2.7 to 2.4 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Failure (TVF) | 290 of 1,187 128 of 612 | 3.5 points -0.6 to 7.5 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Participants With All Target Lesion Revascularization (TLR) | 118 of 1,187 51 of 612 | 1.6 points -1.3 to 4.3 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Participants With All Revascularization | 255 of 1,187 114 of 612 | 2.9 points -1.1 to 6.6 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: Number of Death/All MI/All Revascularization (DMR) | 378 of 1,187 168 of 612 | 4.4 points -0.1 to 8.7 | 1,799 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=191"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=191
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02345161-4218cf4d",
"title": "FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With at Least One On-treatment Bone Fracture Incident in the Treatment Period",
"summary": "4 of 911 against 6 of 899; risk difference -0.2 points, 95% interval -1.1 to 0.5; NCT02345161, A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
"record": "/library/comparisons/NCT02345161-4218cf4d",
"nct_id": "NCT02345161",
"kind": "outcome",
"participants": 1810,
"risk_difference": {
"value": -0.0022833029503448767,
"lower": -0.010540854786253691,
"upper": 0.005455422851425711
},
"group_1": "4 of 911",
"group_2": "6 of 899",
"difference": "-0.2 points",
"interval": "-1.1 to 0.5",
"trial_title": "A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)"
},
{
"id": "NCT02345161-ecddca2d",
"title": "FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With an On-treatment Penumonia Event in the Treatment Period",
"summary": "20 of 911 against 7 of 899; risk difference 1.4 points, 95% interval 0.3 to 2.7; NCT02345161, A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
"record": "/library/comparisons/NCT02345161-ecddca2d",
"nct_id": "NCT02345161",
"kind": "outcome",
"participants": 1810,
"risk_difference": {
"value": 0.014167467450722783,
"lower": 0.002921649465451922,
"upper": 0.02654732502057848
},
"group_1": "20 of 911",
"group_2": "7 of 899",
"difference": "1.4 points",
"interval": "0.3 to 2.7",
"trial_title": "A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=192",
"request_id": "yhaGtOdGncn5ymtn"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant